Sedana Medical's Sedaconda study awarded at DGIIN & ÖGIAIN
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company's pivotal phase III study Sedaconda (SED001) has been named one of the three best posters at the 52nd intensive care conference DGIIN & ÖGIAIN 16–18 June 2021.
"It is very positive that the Sedaconda study is receiving this attention in Germany, which is our largest market. The strong study results form the basis for our ongoing market application and if all goes well, we expect to be able to launch the treatment inhaled sedation in Europe during the second half of this year,” said Jens Lindberg, Acting CEO of Sedana Medical.
DGIIN & ÖGIAIN is the joint annual meeting of the German and Austrian emergency medicine and intensive care societies.
For additional information, please contact:
Jens Lindberg, Acting CEO, +46 72 531 11 17
Susanne Andersson, CFO, +46 73 066 89 04
ir@sedanamedical.com
Sedana Medical is listed on Nasdaq First North Growth Market in Stockholm.
The company's Certified Adviser is Erik Penser Bank, +46 8 463 83 00, certifiedadviser@penser.se.
About Sedana Medical
Sedana Medical AB (publ) develops and sells the medical device AnaConDa for the administration of volatile anaesthetics. Through a combination of AnaConDa and the drug candidate Sedaconda (isoflurane), Sedana Medical provides inhaled sedation for mechanically ventilated intensive care patients. The company has applied for market approval in Europe for Sedaconda and expects an approval in the second half of 2021.
Today, mechanically ventilated intensive care patients are sedated intravenously which leads to several challenges for both patients and care givers. Challenges that are solved by inhaled sedation. Globally, seven to eight million patients are estimated to be sedated in intensive care due to mechanical ventilation, evenly distributed between the US, Europe, and Asia. These patients are on average sedated three to four days. Sedana Medical estimates the total market potential to SEK 20-30 billion. Three years after marketing approval in Europe, Sedana Medical expects sales of SEK 500 million in Europe and an EBITDA margin of about 40 percent. The company has initiated processes to obtain market approval in the US in 2024 and in markets outside the EU.
Sedana Medical has direct sales in Benelux, France, Germany, Great Britain, the Nordics and Spain as well as external distributors in other parts of Europe, Australia, Canada, China, India, Israel, Japan, Mexico and South Korea. The company was founded in 2005 and is headquartered in Stockholm, Sweden, with medical device development in Ireland.